Belatacept for the Management of Moderately Sensitized Patients at Risk for Delayed Graft Function (DGF)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 24 Dec 2018
Price : $35 *
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms BelatPilot
- 13 Dec 2018 Planned End Date changed from 1 Apr 2022 to 9 Oct 2015.
- 13 Dec 2018 Planned primary completion date changed from 1 Apr 2019 to 9 Oct 2015.
- 13 Dec 2018 Status changed from recruiting to withdrawn prior to enrolment.